Clario Boosts Diversity, Cuts Emissions in ESG Report

Published on:
by KnowESG
KnowESG_Clario Boosts Diversity, Cuts Emissions in ESG Report
Image courtesy of Clario

Clario, a leading healthcare research technology company specialising in endpoint technology solutions for clinical trials, has unveiled its second annual Environmental, Social, and Governance (ESG) report.

The report highlights substantial strides in Clario's commitment to sustainability, ethical practices, and responsible governance. Key achievements include a pledge to achieve gender balance within its leadership by 2025 and net-zero emissions by 2045.

Chris Fikry, M.D., the Chief Executive Officer at Clario, expressed pride in the progress outlined in the second ESG report. He emphasised Clario's ongoing dedication to sustainability and accountability in the industry.

Fikry stated, "By fostering workplace diversity, pursuing net-zero emissions, and advancing health equity, we believe we are setting a benchmark for others to aspire to."

Highlights from the report include:

  • Workplace Diversity: As of the end of 2022, women comprised 53% of Clario's workforce, accounting for 57% of promotions. Notably, 35% of employees at the Director level or above were women. Clario aims for gender balance in its global leadership team and a 32% representation of people of colour in its U.S. leadership roles by the end of 2025.

  • Net-Zero Emissions: Clario has made significant strides, achieving a (externally validated) 47% reduction in emissions from purchased electricity by increasing the use of renewable energy sources. Furthermore, there was a 50% reduction in Scope 1 and 2 emissions. The company is committed to achieving net-zero emissions by 2045.

  • Health Equity Advancements: In 2022, Clario prioritised a patient-centric approach in clinical trials, introducing user-friendly instructions, multilanguage support, and a Bring Your Own Device (BYOD) paradigm for efficient data collection. Additionally, Clario addressed health equity disparities in clinical trials by partnering with the Tufts Center for the Study of Drug Development on a research study, with results published in late 2023. The study focused on underrepresentation issues, documenting progress and identifying gaps.

David Fusco, Chief Human Capital Officer at Clario, emphasised the company's belief in the power of diversity to drive continuous improvement in performance and innovation.

Fusco stated, "Diversity and inclusion enhance our ability to serve our customers and drive positive change."

To access Clario's second annual Environmental, Social, and Governance (ESG) report, visit Clario.com.

For more investor-related news

To view and compare company ESG Ratings and Sustainability Reports, visit our Company ESG Profiles page.

Source: Clario

Share:
esg
esg
esg
esg

Investors Headlines

Amtrak Publishes 2023 Sustainability Report

Amtrak Publishes 2023 Sustainability Report

Danske Bank's New Mobile Feature for Sustainable Investing

Danske Bank's New Mobile Feature for Sustainable Investing

Mizuho, LSEG Partner to Grow Carbon Credit Market

Safran to Build a More Sustainable Aerospace Supply Chain

ESG in Private Real Estate: Preqin & Measurabl Tie-Up

AIM Group Publishes First Sustainability Report

APSEZ Earns Top Ranks for Sustainability Efforts

IHS Towers Releases 2023 Sustainability Report

TriNet Earns Top ESG Rating from ISS ESG

PATRIZIA Strengthens ESG Team for Impact Investing